Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2024

Commun Dis Intell (2018). 2025 Feb 19:49. doi: 10.33321/cdi.2025.49.017.

Abstract

The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known, and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

Keywords: Neisseria meningitidis; antimicrobial resistance; disease surveillance; invasive meningococcal disease.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Australia / epidemiology
  • Ceftriaxone / pharmacology
  • Ciprofloxacin / pharmacology
  • Disease Notification
  • Drug Resistance, Bacterial
  • Humans
  • Meningococcal Infections* / epidemiology
  • Meningococcal Infections* / history
  • Meningococcal Infections* / microbiology
  • Microbial Sensitivity Tests
  • Neisseria meningitidis* / classification
  • Neisseria meningitidis* / drug effects
  • Neisseria meningitidis* / genetics
  • Neisseria meningitidis* / isolation & purification
  • Population Surveillance*
  • Serogroup

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Ceftriaxone